Micromet Report issue

For profit Phase 2 Phase 3
Founded: Munich Germany (1993)
Status: Acquired by Amgen (2012)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Micromet (0) Acquired (1)

canvaxin (2 trials)

Drugs in Phase 2 Trials (1)

Key: Micromet (0) Acquired (1)

melanoma vaccine (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 3
  • # of Trial APIs: 2